FDA News

FDA Advisory Group Votes in Favor of Pfizer Investigational Maternal RSV Vaccine Candidate
May 19, 2023

The Pfizer vaccine RSVpreF administered to pregnant people was judged by the advisory committee to be effective at preventing RSV in infants from birth to 6 months.

First RSV Vaccine Brings "Sense of Relief" to Public Health Experts, Says Immunize.org President
May 19, 2023

Kelly Moore, MD, MPH, says the public health community is relieved by the FDA's approval and excited at "the chance to finally do something about the disease."

Daily Dose: FDA Approves Fezolinetant for Treatment of Hot Flashes Caused by Menopause
May 16, 2023

Your daily dose of clinical news you may have missed.

FDA Approves Novel Drug for the Treatment of Hot Flashes Caused by Menopause
May 15, 2023

Fezolinetant is the first NK3 receptor antagonist approved by the FDA for treatment of moderate-to-severe vasomotor symptoms due to menopause.

FDA Approves Brexpiprazole for Agitation Associated with Alzheimer Dementia
May 12, 2023

Brexpiprazole, an atypical antipsychotic, is the first and only medication approved to treat AD-associated agitation, reported in almost half of people with the disease.

Oral Contraceptive Gets Unanimous Recommendation for OTC Use from FDA Advisory Panel
May 10, 2023

Opill, a progestin-only oral contraceptive, if approved by the FDA, would be the first an only form of birth control in the US available without a physician's prescription.

FDA Approves World's First Vaccine Against Respiratory Syncytial Virus
May 03, 2023

The novel vaccine, from biopharma company GSK, is approved to prevent RSV-associated lower respiratory tract disease in adults aged ≥60 years.

FDA Approves First Oral Microbiota Biotherapeutic for Recurrent C. difficile Infection
April 28, 2023

Vowst is the first and only FDA-approved orally administered microbiota-based therapeutic for the prevention of recurrent C. diff infection in adults.

FDA Clears Omnipod GO Insulin Delivery Device for Persons with Type 2 Diabetes
April 25, 2023

The wearable tubeless insulin delivery device provides a fixed rate of continuous long-acting insulin for 72 hours, requiring no needles or injections.

Atogepant Granted Label Expansion for Prevention of Chronic Migraine
April 19, 2023

The oral calcitonin gene-related peptide receptor antagonist is now indicated for prevention in both episodic and chronic migraine.